Kornimate/medical-research-clean huggingface dataset:
pediatric intubation during emergency conditions

Conditions: Endotracheal Intubation; Pediatric; Cardiac Arrest; Injuries

Summary: the effectiveness of endotracheal intubation in pre-hospital conditions is insufficient - especially in the context of pediatric patients. anatomical differences in pediatric patients compared to adults: a relative larger tongue, a larger and more flabby epiglottis - located more cephalously - that make intubation is more difficult than for adults. also, higher oxygen metabolism requires the immediate response of medical personnel to children in case of need to protect the airways and support breath.


Eligibility criteria:
inclusion criteria: * paramedics * give voluntary consent to participate in the study * none experience in videolaryngoscopy * less than 1 year experience in medicine exclusion criteria: * not meet the above criteria * wrist or low back diseases

Keywords: difficult airway endotracheal intubation chest compression physician
intravitreal triamcinolone and moxifloxacin injection after cataract surgery

Conditions: Pharmacological Action

Summary: this study aims to evaluate the short-term effects and safety of prophylactic intra-vitreal injection of triamcinolone-moxifloxacin combination after cataract surgery. 84 patients underwent cataract surgery associated with intra-vitreal injection of triamcinolone-moxifloxacin combination after surgery.

all the patients underwent the surgical removal of cataract by the same surgeon according to the standard protocols for modern phacoemulsification. surgery was done under local anesthesia by peri-bulbar injection of local anesthetic. all operations were performed in an operating room by using an operating microscope under complete aseptic condition by using 10% povidone iodine solution applied to the skin of eye lid, eye lashes, side of the nose, eye brow and the skin of forehead. before the operation, sterile drape and eyelid speculum were used, then 5% povidone iodine solution was applied to the bulbar conjunctiva and fornices for about 5 minutes, then was irrigated by balanced salt solution (bss). all the patients were followed up at the 1st day, 1st week, 1st month and at the 3rd month after the operation. at each visit the followings should be assessed: the post-operative refraction, the best corrected visual acuity and anterior and posterior segments examination for any sign of postoperative inflammation as cells and flare. intra-ocular pressure (iop) assessment and optical coherence tomography (oct) images were also taken at the 1st and the 3rd postoperative months to assess the central macular thickness in suspected cases of cystoid macular edema (cme) based upon symptoms or signs observed on fundus examination, were confirmed by oct of the macula through subjective interpretation via presence of cysts or an objective measurement of retinal thickness \> 250 microns.

Eligibility criteria:
inclusion criteria: patients underwent uncomplicated cataract surgery with: * a significant cataract. * good control of diabetes mellitus (dm) and hypertension (hpt) if present. * visual acuity not less than hand movement (hm). exclusion criteria: the followings were the exclusion criteria: * the use of systemic or topical steroids, topical ophthalmic antibiotics, or non-steroidal anti-inflammatory drugs (nsaids) for one week before operation. * make an additional procedure at the same time with cataract surgery. * those with uncontrolled glaucoma or with marked visual field defect . * those with a significant macular edema due to dm, hpt, retinal vein occlusion (crvo) or due to any previous inflammatory condition. * those with blepharitis or any other local disease interfering with surgical intervention or affecting on the surgical outcome. * occurrence of intraoperative complications as posterior capsular rupture or postoperative complications as retained lens fragment.

Keywords: endophthalmitis
clinical evaluation of nx-1207 for the treatment of benign prostatic hyperplasia (bph)

Conditions: Benign Prostatic Hyperplasia

Summary: this study will evaluate the safety and efficacy of a 2.5 mg dose of nx-1207 for the treatment of bph (benign prostatic hyperplasia) as compared to placebo.


Eligibility criteria:
inclusion criteria: 1. provide signed informed consent prior to enrolment in the study 2. ipss ≥ 15 3. prostate volume ≥ 30 ml ≤ 70 ml 4. qmax \< 15 ml/sec based on a minimum void of 125 ml 5. agree not to use any other approved or experimental bph or oab medication anytime during the study exclusion criteria: 1. history of illness or condition that may interfere with study or endanger subject 2. use of prescribed medications that may interfere with study or endanger subject 3. presence of a median lobe of the prostate 4. previous surgery or mist for treatment of bph 5. post-void residual urine volume \> 200 ml 6. psa ≥ 10 ng/ml; prostate cancer must be ruled out (negative biopsy) for psa ≥ 4 ng/ml 7. participation in a study of any investigational drug or device within the previous 90 days 8. prostate cancer

Keywords: benign prostatic hyperplasia bph enlarged prostate
dual task training in parkinson's disease

Conditions: Parkinson Disease

Summary: the aim of study is to analyze the effects of dual task training on balance, gait, cognition and neurotrophic factors in parkinson's disease.

20 patients diagnosed with parkinson's disease will be randomly assigned to either intervention or control group. and 10 healty subjects will be included to study in order to determine the reference values.the intervention group will be recieved cognitive and motor dual task training consisting of balance and walking activities 3 days a week for 8 weeks. control group will be recieved same balance and walking activities in single task condition 3 days a week for 8 weeks. in order to evaluate the effects of the training, evaluations will be performed before and after the training period.

Eligibility criteria:
inclusion criteria: * at least 40 years of age * neurologist-diagnosed parkinson's disease * hoehn \& yahr (h\&y) stages 1 to 3 * 24 or more mini mental status examination score. exclusion criteria: * other neurologic disorder * cardiovascular, inflammatory,vestibular or musculoskeletal problems that could prevent them to participate in an exercise program * had deep brain stimulation history * visual, auditory, orientational problems that could affect study results
esophageal capsaïcin infusion and mucosal integrity

Conditions: TRPV1 Protein, Human; Capsaicin; Electric Impedance; Esophagus; Intracellular Space; Pain Measurement; Microscopy, Electron

Summary: reflux is common, especially after large meals. in general, this can do no harm. however, if reflux occurs often and causes troublesome symptoms and or complications, it is called gastroesophageal reflux disease (gerd). long exposure to gastric acid causes the mucosa of the esophagus to loose its integrity, which is thought to lead to the symptom of heartburn. several food products can also impair the esophageal mucosa integrity and thereby influence reflux symptoms. one of these products is capsaicin, the pungent ingredient of red peppers. use of capsaicin often leads to worsening of complaints in patients with gerd and can cause symptoms in healthy volunteers, possibly due to its effect on the mucosal integrity. in this study the investigators want to investigate the effect of capsaicin infusion on mucosal integrity. the investigators will evaluate mucosal impedance and the histology of the esophageal mucosa. in addition, the investigators also aim to assess the involvement of the trpv1 receptor by evaluating the possible release of neuropeptides in the esophageal mucosa.


Eligibility criteria:
inclusion criteria: * no history of gastrointestinal disease, especially gastro-esophageal reflux disease. * bmi = 18-25 kg/m² * caucasian race * subject signed the informed consent form and is able to adhere to study protocol exclusion criteria: * age \<18 years * erosive esophagitis or gastric ulceration during endoscopy on ppi in the past or during the experiment * use of regular (\> 1 x per week) dietary capsaïcin (in additives as tabasco/sambal/chili sauce or indian, mexican or thai food dishes) * allergy to capsaïcin * use of medication affecting gi function (prokinetics) or antisecretory medication (ppi) within 3 days prior to endoscopy. * multisystem diseases (including severe cardiopulmonary disease, collagen diseases, coagulation disorders) * esophageal motility disorders * previous esophageal or gastric surgery * use of anticoagulants or a history of coagulopathy * pregnancy * history of alcohol abuse or current excessive alcohol consumption (\> 2 alcoholic beverages per day or \> 14 alcoholic beverages per week)
persistence of hepatitis b antibody levels & immune response to a hepatitis b vaccine challenge

Conditions: Hepatitis B

Summary: the purpose of this study is to determine at 5 years of age the persistence of immunity to hepatitis b that was conferred by infant vaccination with infanrix hexa™. the protocol posting has been updated in order to comply with the fda amendment act, sep 2007.


Eligibility criteria:
inclusion criteria: * subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol * a male or female of 4 to 5 years of age at the time of enrolment. * with documented evidence of previous vaccination with four consecutive doses of infanrix hexa™ in germany. * written informed consent obtained from the parents or guardians of the subject at the time of enrolment. * healthy subjects as established by medical history and clinical examination before entering into the study. exclusion criteria: * concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product . * evidence of previous hepatitis b booster vaccination since administration of the fourth dose of infanrix hexa™ booster in the second year of life. * history of or intercurrent hepatitis b disease. * hepatitis b vaccination at birth. * planned administration/administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before booster vaccination and ending 30 days after. * administration of immunoglobulins and/or any blood products within the three months preceding booster vaccination or planned administration during the study period. * chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the hbv vaccine challenge.
intratympanic steroids for sudden hearing loss

Conditions: Dexamethasone or Methylprednisolone; Sudden Hearing Loss; Intratympanic Steroid

Summary: for patients with sudden hearing loss, the initial treatment is not usually effective. we use dexamethasone or methylprednisolone to be an intratympanic steroid administration as a salvage treatment. an randomized, double-blind, multi-center study is designed to find the difference between dexamethasone or methylprednisolone.


Eligibility criteria:
inclusion criteria: sudden hearing loss and initial treatment is not effective exclusion criteria: the patients refused intratympanic steroids treatment.
endometriosis and pain

Conditions: Endometriosis

Summary: endometriosis is a condition affecting about 10% of childbearing age women. it can begin a few months to a few years after puberty. it causes abdominal and pelvic pain that can be extremely debilitating, affecting the quality of patients life by affecting sexuality and fertility. psychological repercussions are very important and underestimated. patient care focuses most often on the "organ pathology treatment ". this study proposes to evaluate a multidisciplinary patient care by insisting on anatomo-physiological pain management, psychological and bodily, in the perioperative phase. the main objective is to evaluate benefit of psychological and corporal group management on the overall quality of life of patients with severe endometriosis in terms of endometriotic damage and/or functional and painful repercussions, requiring surgery, before or after this study


Eligibility criteria:
inclusion criteria: * patients \>=18 years * patients with deep endometriosis according to the cngof (collège national des gynécologues et obstétriciens français) and/or chronic pain related to endometriosis according to doctor's evaluation and to the definitions of iasp (international association for the study of pain) and has (french national authority for health) in treatment failure despite appropriate medical or surgical management of endometriosis * patients with social security * patients willing to come to all study visits * patients who signed their informed consent exclusion criteria: * patients unable to participate in group care: * patients with social phobia assessed during the inclusion interview * patients with psychiatric disorders of a psychotic nature: delirium, hallucination, incoherent thoughts * patients with behavioral disorders of hetero-aggressive or self-aggressive type opatients with a handicap that prevents them following the physical and psychological group sessions (speech disorders, hearing, visual or practical) * pregnant women * patients planning a change (stop, start) during the study of their psychological management in their current care path. * patients planning a change (stop, start) during the study of their treatment by non-medicinal techniques (auriculo-acupuncture, relaxation and self-hypnosis, transcutaneous neurostimulation by tens) * patients suffering from other severe or chronic somatic diseases associated with endometriosis * patients with cognitive disorders * patients with analgesics addiction (psychoactive substances, morphine substances, etc.) * patients protected by law (under guardianship / trusteeship) * patients participating in another interventional research that may interfere with the protocol results

Keywords: endometriosis pain group management quality of life
maxillary vascular canal thickness and sinus augmentation bleeding

Conditions: Bone Loss

Summary: this study aims to evaluate the relationship between the maxillary intra-osseous vascular canal thickness as measured by volumetric tomography and the amount of intra-operative bleeding during open sinus floor augmentation. a sample of patients will be selected, and their maxillary intra-osseous vascular canal thickness will be measured using volumetric tomography. intraoperative bleeding will be recorded during open sinus floor augmentation. the data will be analyzed to determine if there is a correlation between the thickness of the maxillary intra-osseous vascular canal and intraoperative bleeding.


Eligibility criteria:
inclusion criteria: * maxillary partial or total edentulism, including premolar/molar regions * medically healthy * 2 to 5 mm residual bone height * sufficient bone width to place a standard dental implant (diameter \>4mm) * age: 18-65 years * patients who volunteered to participate in the study and signed written informed consent exclusion criteria: * maxillary sinusitis * acute myocardial infarction in the last 12 months * use of any medication that may inhibit bone healing * history of radiotherapy in the head and neck region * presence of psychiatric problems * smoking more than 10 cigarettes a day * alcoholism * chronic drug use

Keywords: maxillary sinus floor augmentation volumetric computed tomography intra-operative bleeding
endovascular denervation improves limb ischemia in patients with peripheral artery disease

Conditions: PAD

Summary: sympathetic overactivity partly promotes the development of peripheral artery disease which mainly leads to ischemia of the lower limbs. endovascular arterial denervation (ed) is a minimally invasive technique which could deliver radiofrequency energy by a multi-electrode catheter to the lower limb artery to restore sympathetic activity. the purpose of this study is to evaluate the effects of multi-electrode radiofrequency ablation system on lower limb ischemia with pad.

peripheral arterial disease(pad) show insufficient blood supply of diseased limbs, which causes intermittent claudication of lower limbs, reduced skin temperature, pain, and chronic progressive disease that still produces ulcer or necrosis. some clinical studies have shown sympathetic overactivity in the lower arterial ischemic disease. the multi-electrode radiofrequency ablation system can significantly reduce the excitability of sympathetic nerve, restore the normal response of sympathetic nerve, relieve the pain and discomfort of patients, effectively improve the symptoms of lower limb ischemia, and improve the quality of life of patients.

Eligibility criteria:
inclusion criteria: 1. eligible subjects aged 18-75 years, 2. clinically confirmed pad in the lower extremities, 3. rutherford category ii-vi. exclusion criteria: 1. thrombolytic therapy performed within 30 days, 2. patients who had undergone vascular bypass surgery before this study, 3. allergy or contraindication of antiplatelet drugs, anticoagulants, thrombolytic drugs and contrast agents, 4. patients with obvious bleeding tendency, coagulation dysfunction, hypercoagulability and blood system diseases, 5. serious liver and kidney diseases, 6. history of hemorrhagic stroke within last month or ischemic stroke or transient ischemic attack within 2 weeks, 7. pacemaker implants, 8. patients who are pregnant, breast-feeding or planning pregnancy, 9. expected survival \< 24 months.
clinicopathological features of renal cell carcinoma in young patients

Conditions: Clinicopathologic Characters of Renal Cell Carcinoma in Young Patients

Summary: analysis of clinicopathologic characters of renal cell carcinoma in young patients and their influence on the survival outcomes

worldwide, rcc accounts for 2-3% of all adult malignancies and the 8th most commonly diagnosed primary cancer among all adults. representing 3rd place among urinary system tumors. most of rcc occurs in old age while about 7% occurs in younger adults below 40 years. recently the published data about the tumor clinco-pathological features, treatment response and outcomes were different in young adults than older patients, where some data showed favorable features and survivals, while other showed negative ones.

Eligibility criteria:
inclusion criteria: * age \< 40 years * patients proven to have rcc * patients eligible to receive treatment exclusion criteria: * second malignancy.
sonographic evaluation of the single-incision needleless (contasure-needleless®) mini-sling placement to predict success

Conditions: Urinary Incontinence,Stress

Summary: transperineal ultrasonography is gaining importance in preoperative and postoperative evaluation of the patient with urinary incontinence with allowing well detailed information about the anterior compartment. there is little evidence that transperineal sonography can aid surgeons to predict the success or failure after mid-urethral slings. we aimed to investigate the efficacy of sonography in mini-sling operations to predict the success or failure.

women who are scheduled for anti-incontinence operation due to their stress urinary incontinence will be pre- and postoperatively evaluated by transperineal and introital ultrasound. patients will be followed for at least 1 year.

Eligibility criteria:
inclusion criteria: * patients with clinically stress urinary incontinence * patients who claim that their condition severely impair their quality of life * patients who are failed on conservative management (life style changes and pelvic floor exercises) exclusion criteria: * patients who have unregulated diabetes mellitus (they will be included after appropriate and sustainable blood glucose regulation) * patients who have neurological condition that may affect the incontinence * patients who have psychiatric disease that may affect the subjective evaluation.

Keywords: pelvic floor ultrasonography transperineal ultrasound introital ultrasound mini-sling needleless urinary incontinence,stress
study of the initial combination of bosentan with iloprost in the treatment of pulmonary hypertension patients

Conditions: Pulmonary Arterial Hypertension

Summary: previous studies suggest that combinations of existing therapies may be effective for pulmonary arterial hypertension (pah). however, all of these studies are sequential combination therapy, for example, by adding sildenafil to previously prescribed bosentan. this kind of therapy model is not enough for pah patients, especially those with new york heart association (nyha) class ⅲ and ⅳ. in this randomized, multicenter study, the investigators evaluate the safety and efficacy of combining inhaled iloprost, a prostacyclin analog, with the endothelin receptor antagonist bosentan in treatment naive patients with pah by comparing with bosentan monotherapy. efficacy endpoints include change from baseline in 6-min-walk distance (6-mwd), modified (nyha) functional class, hemodynamic parameters, and time to clinical worsening.


Eligibility criteria:
inclusion criteria: * aged 10 to 80 * treatment naive symptomatic pah * 6-mwd of 100-425 m * resting mean pulmonary artery pressure greater than 25 mm hg, pulmonary capillary wedge pressure less than 15 mm hg, and pulmonary vascular resistance of 240 dyn.s.cm-5 or greater. exclusion criteria: * patients with thromboembolic disease, * untreated obstructive sleep apnea, * portal hypertension, * chronic liver disease or renal insufficiency, * left-sided or unrepaired congenital heart disease, * substantial obstructive (fev1/fvc\<50% predicted) or restrictive (total lung capacity\<60% predicted) lung disease * patients receiving phosphodiesterase inhibitors or other prostanoids and endothelin receptor antagonists

Keywords: treatment of
evaluation of the efficacy and safety of vx-864 in subjects with the pizz genotype

Conditions: Alpha1-Antitrypsin Deficiency

Summary: this study will evaluate the efficacy, safety and pharmacokinetics (pk) of vx-864 in pizz subjects.


Eligibility criteria:
key inclusion criteria: * subjects must have a pizz genotype confirmed at screening * plasma aat levels indicating severe deficiency at screening key exclusion criteria: * history of a medical condition that could negatively impact the ability to complete the study * solid organ, or hematological transplantation or is currently on a transplant list * history of use of gene therapy or rnai therapy at any time previously other protocol defined inclusion/exclusion criteria may apply
influence of adiponutrin in chronic liver disease

Conditions: Alcoholic Liver Disease

Summary: increasing evidence attests the influence of multiple metabolic genetic risk factors in the progression of alcoholic liver disease. deleterious pathways involved in metabolism such as lipid peroxidation and cytokines have been implicated in promoting inflammation leading to fibrosis increase and liver injury progression. the aim of this study was to assess the role of rs738409 single nucleotide polymorphism in the pnpla3 gene in alcoholic liver disease patients.


Eligibility criteria:
ald patients: inclusion criteria: * excess alcohol intake * abnormal alanine aminotransferase (alt) and aspartate aminotransferase (ast) or a suspicion of cirrhosis related to ald * caucasian ethnicity exclusion criteria: * presence of any other chronic liver disease * co-infection with human immunodeficiency virus controls: inclusion criteria: * caucasian ethnicity exclusion criteria: * presence of a disease

Keywords: pnpla3 fibrosis cirrhosis alcoholic liver disease